Risk factors

Marvell Technology faces key risks from AI, Cloud, and 5G market fluctuations and potential customer insourcing. The company carries $4.1 billion in debt as of February 1, 2025, alongside significant intangible assets. International operations and trade restrictions regarding China present ongoing operational challenges.

NextNav faces ongoing net losses, posting $101.9 million in 2024 and relying heavily on external financing and debt.

Neostellar Capital focuses on venture capital-backed emerging companies, relying heavily on private equity and venture capital investments.

InspireMD reports recurring net losses, including $32.0 million for 2024, and holds an accumulated deficit of $254 million. The company relies heavily on the success, FDA approval, and self-commercialization of the CGuard Prime carotid stent system. Operations in Israel expose the company to regional geopolitical conflicts and currency exchange risks.

The risk section is dominated by customer concentration in automotive manufacturing, driver shortages, fuel price volatility, and regulatory compliance.

The company's risk profile is heavily dominated by credit exposure in real estate lending within the Catawba Valley region, reliance on customer deposits for funding, and strict regulatory oversight.

Credit exposure centers on New Jersey, Pennsylvania, New York City, commercial real estate, and New York multifamily lending.

Pagaya Technologies faces heavy concentration risk from a small number of lending partners and reliance on the securitization market. The company incurred a U.S. GAAP net loss of $401.4 million in 2024. Operations span unsecured personal loans, auto loans, and single-family rental real estate markets.

Quest Resource Holding faces concentration risk with its largest customers accounting for substantial revenue portions.

Company faces cyclicality in commercial and business aviation markets, dependency on a small number of OEM customers, and complex regulatory and environmental compliance obligations.

Solo Brands faces going concern doubts due to a $113.4 million net loss and $150.7 million in debt in 2024. The company relies heavily on the Solo Stove segment, which saw declining sales due to a lack of new products. Limited liquidity demands significant management attention while tying up operational flexibility.

The company relies heavily on the GSK License Agreement for ibrexafungerp commercialization and revenue.